Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 5/20 | 0.52 |
| ▸ | MMP13 | P45452 | 5/20 | 0.52 |
| ▸ | MMP2 | P08253 | 4/20 | 0.52 |
| ▸ | MMP3 | P08254 | 4/20 | 0.52 |
| ▸ | MMP1 | P03956 | 3/20 | 0.52 |
| ▸ | MMP7 | P09237 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | HPN | P05981 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3908110 | 0.90 | MMP13 (0.53) | MMP9MMP13MMP2MMP3MMP1 | |
| SCHEMBL3914344 | 0.90 | MMP2 (0.53) | MMP9MMP13MMP2MMP3MMP1 | |
| SCHEMBL3907752 | 0.86 | CAPN1 (0.49) | GAAMMP9MMP13MMP2MMP3 | |
| SCHEMBL3917869 | 0.84 | CAPN1 (0.54) | MMP9MMP13MMP2MMP3MMP1 | |
| SCHEMBL23234551 | 0.84 | CTSB (0.57) | CTSBCAPN1CTSL | |
| SCHEMBL7268524 | 0.83 | GAA (0.54) | GAAMMP9MMP13MMP2MMP3 | |
| SCHEMBL18231229 | 0.82 | CA2 (0.61) | GAAMMP9MMP2CTSBALDH1A1 | |
| SCHEMBL21538575 | 0.82 | CA2 (0.61) | GAAMMP9MMP2CTSBALDH1A1 | |
| SCHEMBL20204722 | 0.81 | CTSB (0.62) | CTSBCAPN1CTSL | |
| Hydrochloric Acid SCHEMBL7268747 | 0.79 | GAA (0.48) | GAAMMP9MMP13MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572833-B2 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-11 | — | — | US | disclosed |
| EP-1504760-B1 | Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy | SENJU PHARMA CO (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-7052714-B1 | Ophthalmic adhesive preparations for percutaneous adsorption | SENJU PHARMACEUTICAL CO., LTD (JP) | 2006-05-30 | — | — | US | disclosed |
| EP-1058553-B1 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH OCULAR FUNDUS TISSUE CYTOPATHY | SENJU PHARMA CO (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1504760-A1 | Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy | Senju Pharmaceutical Co., Ltd. (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1064021-B1 | USE OF CYSTEINPROTEASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND TREATMENT OF BRAIN TISSUE IMPAIRMENT DUE TO HYPERTENSIVE ENCEPHALOPATHY OR ENCEPHALOTHLIPSIS. | SENJU PHARMA CO (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1334718-A1 | DRUG COMPOSITION COMPRISING DIPEPTYDYL ALDEHYDE DERIVATIVE | Senju Pharmaceutical Co., Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-0927716-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6551999-B1 | For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-1221315-A1 | OPHTHALMIC ADHESIVE PREPARATIONS FOR PERCUTANEOUS ABSORPTION | Senju Pharmaceutical Co., Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-6342531-B1 | ANTICOAGULANTS, HEMOSTATIC, ANTIISCHEMIC, HYPOTENSIVE, ANTITUMOR, ANTIARRHYTHMIC AGENTS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-29 | — | — | US | disclosed |
| US-6214800-B1 | ANGIOGENESIS INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| EP-1064021-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A CYSTEINE PROTEASE INHIBITOR FOR PROPHYLAXIS AND THERAPY OF BRAIN TISSUE IMPAIRMENT | Senju Pharmaceutical Co., Ltd. (JP) | 2001-01-03 | — | — | EP | disclosed |
| EP-1058553-A2 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH OCULAR FUNDUS TISSUE CYTOPATHY | Senju Pharmaceutical Co., Ltd. (JP) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999048522-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A CYSTEINE PROTEASE INHIBITOR FOR PROPHYLAXIS AND THERAPY OF BRAIN TISSUE IMPAIRMENT | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999044624-A2 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH OCULAR FUNDUS TISSUE CYTOPATHY | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-10 | — | — | WO | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | DPP4, DPP3, DPP7 | GAA 618/4885MMP9 589/4885MMP13 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.